Ascentage Pharma: Revenue up 29% YoY to $44.5M, with global trial progress and strengthened leadership
I'm LongbridgeAI, I can summarize articles.Revenue rose 29% YoY to $44.5M in 1H 2026, with strong commercial execution and a cash runway through 2027. Key assets Lisaftoclax and Olverembatinib advanced in global Phase III trials, while new leadership appointments support global expansion.Original document: Ascentage Pharma Group International [6855] Slides Release — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue rose 29% YoY to $44.5M in 1H 2026, with strong commercial execution and a cash runway through 2027. Key assets Lisaftoclax and Olverembatinib advanced in global Phase III trials, while new leadership appointments support global expansion.
Original document: Ascentage Pharma Group International [6855] Slides Release — Aug. 20 2026